Curated News
By: NewsRamp Editorial Staff
February 10, 2026

NanoViricides Seeks Orphan Drug Status for Measles Treatment Amid Global Outbreaks

Discuss on Substack
Original Source

TLDR

  • NanoViricides seeks FDA orphan drug designation for NV-387 against measles, potentially securing tax credits, fee exemptions, and seven years of market exclusivity for competitive advantage.
  • NanoViricides filed an orphan drug application with the FDA for NV-387, a broad-spectrum antiviral candidate, using nanoviricide technology licensed from TheraCour for targeted measles treatment.
  • NanoViricides' measles treatment application addresses rising global cases, potentially improving public health outcomes and offering a new therapeutic option to combat this preventable disease.
  • NanoViricides' nanoviricide technology creates special nanomaterials for antiviral therapy, with NV-387 targeting measles and other viruses like RSV, COVID, and influenza in clinical development.

Impact - Why it Matters

This development matters because measles, a highly contagious and potentially severe disease, is experiencing a dangerous resurgence worldwide due to declining vaccination rates. The pursuit of an Orphan Drug Designation for NV-387 represents a strategic effort to accelerate the development of a novel therapeutic option where few exist. Current treatment is primarily supportive care, making an effective antiviral a critical unmet medical need. Success could not only provide a new tool for doctors managing complex cases and outbreaks but also validate NanoViricides' broader nanoviricide platform technology. This platform aims to tackle multiple other significant viral threats, including RSV, influenza, and future coronaviruses. For public health systems, a new measles treatment could help control outbreaks, reduce complications like pneumonia and encephalitis, and lower healthcare burdens. For investors and the biotech sector, it highlights ongoing innovation in antiviral research, though the inherent high-risk nature of drug development remains a key consideration.

Summary

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral developer, has taken a significant step in addressing a resurgent global health threat by filing an application with the U.S. Food and Drug Administration's Office of Orphan Products Development. The company is seeking Orphan Drug Designation for its lead drug candidate, NV-387, as a treatment for measles. This designation, if granted, would provide crucial incentives including tax credits for clinical trials, exemptions from certain FDA user fees, and up to seven years of market exclusivity upon approval. This move comes amid a concerning rise in measles cases both in the United States and globally, highlighting the urgent need for new therapeutic options. The company's business model is built on licensing proprietary nanoviricide technology from TheraCour Pharma, Inc., focusing on creating special purpose nanomaterials for antiviral therapy.

NanoViricides describes NV-387 as a broad-spectrum antiviral drug with a development pipeline targeting a wide array of viral infections. Beyond measles, the company plans to develop NV-387 for respiratory syncytial virus (RSV), COVID-19, Long COVID, Influenza, other respiratory viral infections, and MPOX/Smallpox. Another advanced candidate, NV-HHV-1, is intended for the treatment of Shingles. The company's expansive portfolio also includes research into drugs for oral and genital Herpes, viral eye diseases, various influenza strains, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. It holds exclusive, perpetual licenses for its platform technology targeting numerous specific viruses. The company is currently focused on advancing NV-387 into Phase II human clinical trials, though it cautions that the drug development path is lengthy, capital-intensive, and success is not guaranteed.

The news was disseminated via BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio of IBN (InvestorBrandNetwork) that focuses on the biotechnology and life sciences sectors. BioMedWire provides services including wire distribution, editorial syndication, press release enhancement, and social media distribution to help companies reach investors and the public. For more details, readers can view the full press release. It's important to note the inherent risks in pharmaceutical development, as there is no assurance that any of NanoViricides' candidates will prove sufficiently effective and safe for human use or successfully navigate clinical trials to become a marketed product.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Seeks Orphan Drug Status for Measles Treatment Amid Global Outbreaks

blockchain registration record for this content.